Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma Vaccines
Researchers from National Institutes of Health publish new studies and findings in the area of melanoma vaccines
September 23rd, 2008
New investigation results, 'Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines,' are detailed in a study published in Clinical Cancer Research. In this recent study, researchers in the United States conducted a study "To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic melanoma treated with high-dose bolus i.v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines. 684 consecutive patients with metastatic melanoma received high-dose bolus i.v." "IL-2 either alone or in conjunction with a variety of melanoma vaccines....
Source: Cancer Weekly (2008-09-23)
|
